Aspiriant LLC Portfolio Shifts: Significant Purchases & Sales in Q2 2026
Aspiriant, Llc's portfolio saw notable adjustments this quarter with increased holdings in large-cap tech and healthcare ETFs like IVV and VGT/VUG alongside reductions in bond funds such as ACWV.
Introduction
Aspiriant, Llc is a significant institutional investor whose quarterly portfolio activities provide insight into its investment strategy. This analysis focuses on the changes observed during Q2 2026 based on available data.
Overall Portfolio Context
The total value of Aspiriant's portfolio stood at $4.05 billion as of June 30, 2026. The fund holds a diverse range of assets including stocks and exchange-traded funds (ETFs), with its largest position being in the ISHARES TR (IVV) fund.
Significant Purchases This Quarter
This quarter, Aspiriant demonstrated notable buying activity across several sectors. The most significant purchase was observed in Vanguard ETFs focused on large-cap equities:
- ISHARES TR (IVV) showed a substantial increase of approximately $645 million, representing a nearly 30% share change and now accounting for about 15.9% of the portfolio.
- VANGUARD WORLD FD (VGT) experienced an extraordinary increase, with a nearly 700% change in shares and its allocation rising to just under 0.3%.
In addition to large-cap equities, Aspiriant also increased exposure to specific ETFs:
- VANGUARD INDEX FDS (VUG) saw a significant increase of about 491% in shares, boosting its portfolio allocation.
Notable Sales and Reductions This Quarter
Conversely, Aspiriant also reduced positions during this period. The most substantial reduction occurred within the bond fund category:
- ISHARES TR (ACWV) experienced a nearly 23% decrease in shares, resulting in a significant reduction of its portfolio allocation.
The fund also sold or reduced positions in other areas:
- ISHARES INC (IEMG) saw a reduction of about 0.37% from its portfolio.
Detailed Holdings Changes
The following table summarizes the key changes observed in Aspiriant's holdings during Q2 2026:
| Symbol | Description | % Change in Shares | New Portfolio Allocation % |
|---|---|---|---|
| Purchases: | |||
| IVV | ISHARES TR (IVV) | +30.03% | 15.91% (now largest position) |
| VGT | VANGUARD WORLD FD (VGT) | +699.99% | 0.30% (significant increase) |
| VUG | VANGUARD INDEX FDS (VUG) | +490.9% | 0.15% (significant increase) |
| Sales/Reductions: | |||
| ACWV | ISHARES TR (ACWV) | -0.23% | 7.22% (now below 10%) |
| IEMG | ISHARES INC (IEMG) | -0.37% | 2.18% (now below 5%) |
Conclusion: Aspiriant's Investment Focus
This quarter, Aspiriant appears to have prioritized growth in large-cap equities and specific sector-focused ETFs while reducing exposure to certain bond funds. The significant increase in the Vanguard fund VANGUARD MUN BD FDS (VTEB) also suggests continued interest in fixed income, albeit less dramatically than other purchases.
To explore Aspiriant's full investment profile and holdings data further, visit Aspiriant LLC on Insiderset. Detailed information for individual stocks can be found at their respective pages.